Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
KPTI Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Karyopharm Therapeutics Inc.NASDAQ: KPTI
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 78.9% from a year ago
Other current liabilities stood at $3.47M at the end of Q1 FY2026, up 78.9% from a year earlier and up 119.6% from the prior quarter. Over 3 fiscal years it compounded at -34.8% a year.
Context
- Other current liabilities amounted to 2.6% of total assets at the end of Q1 FY2026, up 1.1 pp from a year earlier.
- Other current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +78.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.96M USD
- Year-over-year change
- -61.7%
- 4-year CAGR
- -26.5%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.96M | -61.7% |
| FY2024 | 2024-12-31 | 15.56M | -14.4% |
| FY2023 | 2023-12-31 | 18.16M | -15.4% |
| FY2022 | 2022-12-31 | 21.47M | +5.4% |
| FY2021 | 2021-12-31 | 20.37M | — |
Other Current Liabilities vs competitors
How KPTI compares with its peers on the latest reported figures
- KPTI's Mar 2026 other current liabilities of $3.47M is the 2nd highest of the 4 companies compared; the peer median is $344.83K.
- Its year-over-year change of +78.9% is the 3rd highest of 4, against a peer median of +253.1%.
- Other current liabilities amounts to 2.6% of total assets for KPTI, versus a peer median of 6.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $17.06M | +253.1% | -13.3% | 6.3% | |
| Mar 2026 | $3.47M | +78.9% | -34.8% | 2.6% | |
| Mar 2026 | $344.83K | +302478947368420928.0% | — | 6.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding KPTI) | $344.83K | +253.1% | -13.3% | 6.0% | |
Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 190.46M | 135.19M | 52.23M | 62.48M | 60.54M |
| Short-term Investments | 38.16M | 142.78M | 139.21M | 46.24M | 3.2M |
| Net Receivables | 22.5M | 47.09M | 26.96M | 30.77M | 26.18M |
| Inventory | 4.11M | 4.22M | 3.04M | 4.74M | 4.04M |
| Other Current Assets | 6.35M | 20.89M | 12.47M | 12.28M | 9.19M |
| Total Current Assets | 275.61M | 350.16M | 233.92M | 156.49M | 103.15M |
| Property, Plant & Equipment (Net) | 9.56M | 7.38M | 4.88M | 6.28M | 4.65M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 351K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.14M | 633K | 1.64M | 1.64M | 267K |
| Total Non-current Assets | 29.7M | 8.01M | 6.52M | 7.93M | 5.27M |
| Total Assets | 305.31M | 358.17M | 240.44M | 164.42M | 108.42M |
| Account Payables | 1.6M | 2.77M | 3.12M | 5.11M | 4M |
| Short-term Debt | 0 | 0 | 0 | 24.43M | 21.01M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 20.37M | 21.47M | 18.16M | 15.56M | 5.96M |
| Total Current Liabilities | 73.72M | 65.91M | 69.48M | 92.26M | 92.06M |
| Long-term Debt | 169.29M | 170.11M | 170.92M | 162.95M | 205.89M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 72.34M |
| Other Non-current Liabilities | 133M | 132.72M | 133.46M | 88.51M | 25.32M |
| Total Non-current Liabilities | 311.26M | 308.92M | 307.17M | 258.17M | 309.28M |
| Total Liabilities | 384.98M | 374.83M | 376.64M | 350.44M | 401.34M |
| Common Stock | 8K | 12K | 12K | 13K | 14K |
| Retained Earnings | (1.18B) | (1.34B) | (1.49B) | (1.56B) | (1.76B) |
| Accumulated OCI | 191K | (638K) | (161K) | (356K) | 71K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (79.67M) | (16.66M) | (136.21M) | (186.02M) | (292.93M) |
| Total Debt | 180.58M | 179.07M | 177.02M | 194.52M | 233.61M |
| Net Debt | (9.88M) | 43.89M | 124.79M | 132.05M | 173.07M |
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
Intrinsic Alpha fair value
Locked
Current Price
$7.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.